Swiss National Bank
RAPT

Swiss National Bank’s RAPT Therapeutics RAPT Stock Holding History

Swiss National Bank’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-5,500
Closed -$395K – 2503
2024
Q1 		$395K Hold
5,500
– – ﹤0.01% 2485
2023
Q4 		$1.09M Sell
5,500
-638
-10% -$79K ﹤0.01% 2189
2023
Q3 		$816K Buy
6,138
+538
+10% +$87.8K ﹤0.01% 2353
2023
Q2 		$838K Sell
5,600
-2,188
-28% -$341K ﹤0.01% 2385
2023
Q1 		$1.14M Sell
7,788
-862
-10% -$174K ﹤0.01% 2178
2022
Q4 		$1.37M Buy
8,650
+1,625
+23% +$260K ﹤0.01% 2145
2022
Q3 		$1.35M Buy
7,025
+75
+1% +$14.2K ﹤0.01% 2148
2022
Q2 		$1.01M Buy
6,950
+1,275
+22% +$170K ﹤0.01% 2359
2022
Q1 		$998K Buy
5,675
+400
+8% +$75.6K ﹤0.01% 2407
2021
Q4 		$1.55M Buy
5,275
+112
+2% +$29.9K ﹤0.01% 2219
2021
Q3 		$1.28M Sell
5,163
-225
-4% -$59.5K ﹤0.01% 2316
2021
Q2 		$1.37M Buy
5,388
+888
+20% +$166K ﹤0.01% 2330
2021
Q1 		$799K Hold
4,500
– – ﹤0.01% 2396
2020
Q4 		$711K Buy
+4,500
New +$978K ﹤0.01% 2409

Other funds holding RAPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Swiss National Bank's RAPT Position: Q2 2024 in Review

Swiss National Bank sold out of RAPT Therapeutics (RAPT) in Q2 2024, closing a stake of 5,500 shares — an estimated $395K sold.

Swiss National Bank first reported a position in RAPT in Q4 2020 and held it in 14 quarters. The position peaked at $1.55M in Q4 2021. 103 funds tracked by Wall St. Rank hold RAPT as of Q2 2024.

  • Swiss National Bank reported no remaining RAPT Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Swiss National Bank sold 5,500 RAPT Therapeutics shares in Q2 2024, an estimated $395K.
  • Swiss National Bank first reported a position in RAPT Therapeutics in Q4 2020 and held it in 14 quarters.
  • Swiss National Bank's RAPT Therapeutics position peaked at $1.55M in Q4 2021.
  • 103 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q2 2024.

Based on Swiss National Bank's 13F filing for Q2 2024, filed 8 Aug 2024.